Differentiation-defective mutants of mouse embryonal carcinoma cells: Response to hexamethylenebisacetamide and retinoic acid

Peter A. McCue, Klaus I. Matthaei, Makoto Taketo, Michael I. Sherman

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

We have generated by mutagenesis eight differentiation-defective sublines from three murine embryonal carcinoma (EC) cell lines. These mutants grossly resemble parental cells in the absence of inducers of differentiation. Based upon response to retinoic acid (RA) or hexamethylenebisacetamide (HMBA), the mutants can be grouped into three types: (a) RA-selected cells that lack cellular RA binding protein (cRABP) activity and fail to differentiate in response to RA or HMBA; (b) RA- or HMBA-selected cells that possess cRABP but differentiate poorly, if at all, in the presence of RA or HMBA; and (c) cells originally selected for lack of response to HMBA but which retain cRABP and the ability to differentiate in response to RA.

Original languageEnglish
Pages (from-to)416-426
Number of pages11
JournalDevelopmental Biology
Volume96
Issue number2
DOIs
StatePublished - Apr 1983

Keywords

  • Acetamides/pharmacology
  • Animals
  • Carrier Proteins/metabolism
  • Cell Differentiation/drug effects
  • Cell Line
  • Mice
  • Mutation
  • Plasminogen Activators/metabolism
  • Receptors, Retinoic Acid
  • Teratoma/genetics
  • Tretinoin/pharmacology

Fingerprint

Dive into the research topics of 'Differentiation-defective mutants of mouse embryonal carcinoma cells: Response to hexamethylenebisacetamide and retinoic acid'. Together they form a unique fingerprint.

Cite this